A Phase I/II Study for Analytic Validation of 89Zr-J591 ImmunoPET as a Molecular Imaging Agent for Metastatic Prostate Cancer

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Clinical Cancer Research

• Publication date

  2015-07-14

• Fields of study

  Medicine

• Identifiers
  DOI 10.1158/1078-0432.CCR-15-0552PMID 26175541PMCID PMC4668231
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Noninvasive Imaging of PSMA in Prostate Tumors with 89Zr-Labeled huJ591 Engineered Antibody Fragments: The Faster Alternatives

  2014cited by this paper
• Diagnostic accuracy of FDG-PET cancer screening in asymptomatic individuals: use of record linkage from the Osaka Cancer Registry

  2014cited by this paper
• 11C-Choline PET/CT detects the site of relapse in the majority of prostate cancer patients showing biochemical recurrence after EBRT

  2014cited by this paper
• 89Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer

  2014cited by this paper
• Comparison of PET imaging with a 68Ga-labelled PSMA ligand and 18F-choline-based PET/CT for the diagnosis of recurrent prostate cancer

  2013cited by this paper
• 11C-Acetate PET/CT Before Radical Prostatectomy: Nodal Staging and Treatment Failure Prediction

  2013cited by this paper
• Baseline 18F-FDG PET/CT Parameters as Imaging Biomarkers of Overall Survival in Castrate-Resistant Metastatic Prostate Cancer

  2013cited by this paper
• Limits of Tumor Detectability in Nuclear Medicine and PET

  2012cited by this paper
• C11-Acetate and F-18 FDG PET for Men With Prostate Cancer Bone Metastases: Relative Findings and Response to Therapy

  2011cited by this paper
• [11C]-choline PET/CT in imaging locally advanced prostate cancer.

  2011cited by this paper
• [11C]Choline PET/CT detection of bone metastases in patients with PSA progression after primary treatment for prostate cancer: comparison with bone scintigraphy

  2011cited by this paper
• The potential of FDG-PET/CT for detecting prostate cancer in patients with an elevated serum PSA level

  2011cited by this paper
• 18F-Fluoromethylcholine (FCH) PET imaging in patients with castration-resistant prostate cancer: prospective comparison with standard imaging

  2010cited by this paper
• Conjugation and radiolabeling of monoclonal antibodies with zirconium-89 for PET imaging using the bifunctional chelate p-isothiocyanatobenzyl-desferrioxamine

  2010cited by this paper
• Imaging , Diagnosis , Prognosis Prognostic Value of Baseline [ 18 F ] Fluorodeoxyglucose Positron Emission Tomography and 99 mTc-MDP Bone Scan in Progressing Metastatic Prostate Cancer

  2010cited by this paper
• 18F choline PET/CT in the preoperative staging of prostate cancer in patients with intermediate or high risk of extracapsular disease: a prospective study of 130 patients.

  2010cited by this paper
• 89Zr-DFO-J591 for ImmunoPET of Prostate-Specific Membrane Antigen Expression In Vivo

  2010cited by this paper
• Antibody Mass Escalation Study in Patients with Castration-Resistant Prostate Cancer Using 111In-J591: Lesion Detectability and Dosimetric Projections for 90Y Radioimmunotherapy

  2008cited by this paper
• Phase I Evaluation of J591 as a Vascular Targeting Agent in Progressive Solid Tumors

  2007cited by this paper
• Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors.

  2007cited by this paper
• Fluorodeoxyglucose Positron Emission Tomography as an Outcome Measure for Castrate Metastatic Prostate Cancer Treated with Antimicrotubule Chemotherapy

  2005cited by this paper
• Pilot Trial of Unlabeled and Indium-111–Labeled Anti–Prostate-Specific Membrane Antigen Antibody J591 for Castrate Metastatic Prostate Cancer

  2005cited by this paper
• Tumor localization of 16beta-18F-fluoro-5alpha-dihydrotestosterone versus 18F-FDG in patients with progressive, metastatic prostate cancer.

  2004cited by this paper
• Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer.

  2004cited by this paper
• Tumor Localization of 16β-18F-Fluoro-5α-Dihydrotestosterone Versus 18F-FDG in Patients with Progressive, Metastatic Prostate Cancer

  2004cited by this paper
• Targeting metastatic prostate cancer with radiolabeled monoclonal antibody J591 to the extracellular domain of prostate specific membrane antigen.

  2003cited by this paper
• Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen.

  2003cited by this paper
• Current evaluation of the tissue localization and diagnostic utility of prostate specific membrane antigen

  1998cited by this paper
• Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma

  1998cited by this paper

• Preclinical Evaluation of a Radiolabeled Anti-PSMA Dimeric Aptamer in a Murine Model of Human Prostate Cancer

  2026cites this paper
• Development and Preclinical Evaluation of a Zirconium-89-Labeled Immunoconjugate for Positron Emission Tomography Imaging of Leukemia Inhibitory Factor in Glioblastoma.

  2025cites this paper
• How a Medicinal Chemistry Project Changed the Way Prostate Cancer is Diagnosed and Treated

  2025cites this paper
• Radionuclides Landscape in Prostate Cancer Theranostics

  2025cites this paper
• Baited SELEX: Drug-Directed Selection of Aptamers to PSMA for In Vivo Targeting of Prostate Cancer Xenografts in Mice.

  2025cites this paper
• Estado del arte y perspectivas futuras de nuevos radionúclidos en Medicina Nuclear: Parte III

  2025cites this paper
• State of the art and future perspectives of new radinuclides in Nuclear Medicine: Part III.

  2025cites this paper
• Enhancing the therapeutic index of [211At]YF2 with iodo pseudo carrier: A simple strategy for reducing accumulation in kidneys, salivary and lacrimal glands.

  2025cites this paper
• [89Zr]Zr-PSMA-617 PET/CT characterization of indeterminate [68Ga]Ga-PSMA-11 PET/CT findings in patients with biochemical recurrence of prostate cancer: lesion-based analysis

  2024cites this paper
• Prostate-Specific Membrane Antigen: Gateway to Management of Advanced Prostate Cancer.

  2024cites this paper
• Immuno-PET for Glioma Imaging: An Update

  2024cites this paper
• PD-L1 peptides in cancer immunoimaging and immunotherapy.

  2024cites this paper
• Isopeptidic Desferrioxamine Analogues: The Role of Hydroxamate Spacing for Chelation of Zr4+

  2024cites this paper
• Recent Advances in Emerging Radiopharmaceuticals and the Challenges in Radiochemistry and Analytical Chemistry

  2024cites this paper
• Prostate-Specific Membrane Antigen Biology and Pathophysiology in Prostate Carcinoma, an Update: Potential Implications for Targeted Imaging and Therapy

  2024cites this paper
• Synthesis and evaluation of bifunctional DFO2K: a modular chelator with ideal properties for zirconium-89 chelation.

  2024cites this paper
• A Phase 0 Study to Assess the Biodistribution and Pharmacokinetics of a Radiolabeled Antibody Targeting Human Kallikrein 2 in Participants with Metastatic Castration-Resistant Prostate Cancer

  2024cites this paper
• Advances and challenges in immunoPET methodology

  2024cites this paper
• Radiochemical, Computational, and Spectroscopic Evaluation of High-Denticity Desferrioxamine Derivatives DFO2 and DFO2p toward an Ideal Zirconium-89 Chelate Platform.

  2023cites this paper
• Comparison of Diagnostic Value between 99mTechnetium-Methylene Diphosphate Bone Scan and 99mTechnetium-Prostate-specific Membrane Antigen Scan in Patients with Prostate Cancer with Osseous Metastases

  2023cites this paper
• Prostate-Specific Membrane Antigen–Targeting Alpha Emitter via Antibody Delivery for Metastatic Castration-Resistant Prostate Cancer: A Phase I Dose-Escalation Study of 225Ac-J591

  2023cites this paper
• GAD1 contributes to the progression and drug resistance in castration resistant prostate cancer

  2023cites this paper
• DFO-Km: A Modular Chelator as a New Chemical Tool for the Construction of Zirconium-89-Based Radiopharmaceuticals.

  2023cites this paper
• Current Status of Radiolabeled Monoclonal Antibodies Targeting PSMA for Imaging and Therapy

  2023cites this paper
• PSMA Targeted Molecular Imaging and Radioligand Therapy for Prostate Cancer: Optimal Patient and Treatment Issues

  2023cites this paper
• Current and potential roles of immuno-PET/-SPECT in CAR T-cell therapy

  2023cites this paper
• Detection efficacy of [89Zr]Zr-PSMA-617 PET/CT in [68Ga]Ga-PSMA-11 PET/CT-negative biochemical recurrence of prostate cancer

  2023cites this paper
• Molecular Design of 68Ga- and 89Zr-Labeled Anticalin Radioligands for PET-Imaging of PSMA-Positive Tumors.

  2023cites this paper
• Zirconium immune-complexes for PET molecular imaging: Current status and prospects

  2023cites this paper
• Antibody-based radiopharmaceuticals as theranostic agents: an overview.

  2022cites this paper
• Design, Synthesis, and Evaluation of DFO-Em: A Modular Chelator with Octadentate Chelation for Optimal Zirconium-89 Radiochemistry.

  2022cites this paper
• The Role of Radiolabeled Monoclonal Antibodies in Cancer Imaging and ADC Treatment.

  2022cites this paper
• Immuno-PET: Design options and clinical proof-of-concept

  2022cites this paper
• Imaging-Guided Targeted Radionuclide Tumor Therapy: From Concept to Clinical Translation.

  2022cites this paper
• Tumor-Targeting Ability of Novel Anti-Prostate-Specific Membrane Antigen Antibodies

  2022cites this paper
• Current role of prostate-specific membrane antigen-based imaging and radioligand therapy in castration-resistant prostate cancer

  2022cites this paper
• 89Zr-panitumumab combined with 18F-FDG-PET improves detection and staging of head and neck squamous cell carcinoma.

  2022cites this paper
• ImmunoPET: Antibody-Based PET Imaging in Solid Tumors

  2022cites this paper
• Determining Binding Affinity (KD) of Radiolabeled Antibodies to Immobilized Antigens.

  2022cites this paper
• Advances in PSMA theranostics

  2022cites this paper
• Radiopharmaceuticals for PET and SPECT Imaging: A Literature Review over the Last Decade

  2022cites this paper
• Development and Functional Characterization of a Versatile Radio-/Immunotheranostic Tool for Prostate Cancer Management

  2022cites this paper
• FAPI PET/CT in the Diagnosis of Abdominal and Pelvic Tumors

  2022cites this paper
• Prostate-Specific Membrane Antigen (PSMA)-Targeted Radionuclide Therapies for Prostate Cancer

  2021cites this paper
• Factors predicting biochemical response and survival benefits following radioligand therapy with [177Lu]Lu-PSMA in metastatic castrate-resistant prostate cancer: a review

  2021cites this paper
• Dosimetry in Clinical Radiopharmaceutical Therapy of Cancer: Practicality Versus Perfection in Current Practice.

  2021cites this paper
• 89Zr-labeled PSMA ligands for pharmacokinetic PET imaging and dosimetry of PSMA-617 and PSMA-I&T: a preclinical evaluation and first in man

  2021cites this paper
• Progress in diagnosis of bone metastasis of prostate cancer.

  2021cites this paper
• Antibodies and antibody constructs as radiopharmaceuticals

  2021cites this paper
• The History of Prostate-Specific Membrane Antigen as a Theranostic Target in Prostate Cancer: The Cornerstone Role of the Prostate Cancer Foundation

  2021cites this paper
• Monoclonal antibody based radiopharmaceuticals for imaging and therapy.

  2021cites this paper
• [89Zr]Zr-huJ591 immuno-PET targeting PSMA in IDH mutant anaplastic oligodendroglioma

  2021cites this paper
• 89Zr-PET imaging in humans: a systematic review

  2021cites this paper
• [68Ga]Ga-PSMA-11: The First FDA-Approved 68Ga-Radiopharmaceutical for PET Imaging of Prostate Cancer

  2021influential citation
• PSMA Theranostics: Current Landscape and Future Outlook

  2021cites this paper
• PSMA-Targeting Radiopharmaceuticals for Prostate Cancer Therapy: Recent Developments and Future Perspectives

  2021cites this paper
• 89Zr as a promising radionuclide and it’s applications for effective cancer imaging

  2021cites this paper
• DFO2: A High-Denticity Chelator for Enhanced Coordination of Zirconium-89

  2021cites this paper
• Molecular Imaging, How Close to Clinical Precision Medicine in Lung, Brain, Prostate and Breast Cancers

  2021cites this paper
• Safety and tolerability of Miltuximab® - a first in human study in patients with advanced solid cancers.

  2021cites this paper
• Preparation of 89Zr Solutions for Radiopharmaceuticals Synthesis

  2021cites this paper
• Review of commonly used prostate specific PET tracers used in prostate cancer imaging in current clinical practice.

  2021cites this paper
• Radiochemistry, Production Processes, Labeling Methods, and ImmunoPET Imaging Pharmaceuticals of Iodine-124

  2021cites this paper
• Inverse electron demand Diels–Alder click chemistry for pretargeted PET imaging and radioimmunotherapy

  2021cites this paper
• Deferoxamine B: A Natural, Excellent and Versatile Metal Chelator

  2021cites this paper
• Molecular Imaging of Newly Diagnosed Prostate Cancer

  2020cites this paper
• PSMA-Based Theranostics: A Step-by-Step Practical Approach to Diagnosis and Therapy for mCRPC Patients.

  2020cites this paper
• 18F-Labeled, PSMA-Targeted Radiotracers: Leveraging the Advantages of Radiofluorination for Prostate Cancer Molecular Imaging

  2020cites this paper
• Targeted alpha therapy with astatine-211-labeled anti-PSCA A11 minibody shows antitumor efficacy in prostate cancer xenografts and bone microtumors

  2020cites this paper
• ImmunoPET: Concept, Design, and Applications.

  2020cites this paper
• Advances in Precision Oncology: Targeted Thorium-227 Conjugates As a New Modality in Targeted Alpha Therapy

  2020cites this paper
• Emerging Subtypes and New Treatments for Castration-Resistant Prostate Cancer.

  2020cites this paper
• Prostate Cancer Theranostics - An Overview

  2020cites this paper
• Current Perspectives on 89Zr-PET Imaging

  2020cites this paper
• Prostate-Specific Membrane Antigen-Targeted Radiopharmaceuticals in Diagnosis and Therapy of Prostate Cancer: Current Status and Future Perspectives

  2020cites this paper
• Imaging Fibroblast Activation Protein Alpha Improves Diagnosis of Metastatic Prostate Cancer with Positron Emission Tomography

  2020cites this paper
• Novel PET imaging methods for prostate cancer

  2020cites this paper
• A simple strategy to reduce the salivary gland and kidney uptake of PSMA targeting small molecule radiopharmaceuticals

  2020cites this paper
• A High-Denticity Chelator Based on Desferrioxamine for Enhanced Coordination of Zirconium-89.

  2020cites this paper
• Meeting report from the Prostate Cancer Foundation PSMA theranostics state of the science meeting

  2020influential citation
• PSA-Targeted Alpha-, Beta-, and Positron-Emitting Immunotheranostics in Murine Prostate Cancer Models and Nonhuman Primates

  2020cites this paper
• Immune-Directed Molecular Imaging Biomarkers.

  2020cites this paper
• Structural Characterization of the Solution Chemistry of Zirconium(IV) Desferrioxamine: A Coordination Sphere Completed by Hydroxides.

  2020cites this paper
• The Radiochemistry of Zirconium

  2020cites this paper
• New Targets for PET Molecular Imaging of Prostate Cancer.

  2019cites this paper
• Intradural-Extramedullary and Intramedullary Spinal Metastases

  2019cites this paper
• Targeting prostate cancer: Prostate‐specific membrane antigen based diagnosis and therapy

  2019cites this paper
• Spinal Cord Tumors

  2019cites this paper
• Recent Advances in Prostate-Specific Membrane Antigen-Based Radiopharmaceuticals.

  2019cites this paper
• GCPII and its close homolog GCPIII: from a neuropeptidase to a cancer marker and beyond.

  2019cites this paper
• Exploitation of CD133 for the Targeted Imaging of Lethal Prostate Cancer

  2019cites this paper
• Ultrasmall Renally-clearable Silica Nanoparticles Target Prostate Cancer.

  2019cites this paper
• First-in-Humans Imaging with 89Zr-Df-IAB22M2C Anti-CD8 Minibody in Patients with Solid Malignancies: Preliminary Pharmacokinetics, Biodistribution, and Lesion Targeting

  2019cites this paper
• Targeted Radioimmunotherapy and Theranostics with Alpha Emitters.

  2019cites this paper
• Utilizing Immunopet To Measure Tumor Response To Treatment In Breast Cancer

  2019cites this paper
• Preclinical Dosimetry, Imaging, and Targeted Radionuclide Therapy Studies of Lu-177-Labeled Albumin-Binding, PSMA-Targeted CTT1403

  2019cites this paper
• Pharmacokinetics and Biodistribution of a [89Zr]Zr-DFO-MSTP2109A Anti-STEAP1 Antibody in Metastatic Castration-Resistant Prostate Cancer Patients.

  2019cites this paper
• Preclinical Efficacy of a PSMA-Targeted Thorium-227 Conjugate (PSMA-TTC), a Targeted Alpha Therapy for Prostate Cancer

  2019cites this paper
• Medical imaging modalities using nanoprobes for cancer diagnosis: A literature review on recent findings

  2019cites this paper
• Imaging Patients with Metastatic Castration-Resistant Prostate Cancer Using 89Zr-DFO-MSTP2109A Anti-STEAP1 Antibody

  2019cites this paper